HC Wainwright Increases Radius Health Inc. (RDUS) Price Target to $71.00
Radius Health Inc. (NASDAQ:RDUS) had its target price lifted by analysts at HC Wainwright from $55.00 to $71.00 in a report issued on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 25.15% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. restated a “buy” rating and issued a $70.00 price objective on shares of Radius Health in a research report on Friday, August 5th. Cowen and Company restated a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, Jefferies Group restated a “hold” rating and issued a $46.00 price objective on shares of Radius Health in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $63.51.
Shares of Radius Health (NASDAQ:RDUS) opened at 56.73 on Wednesday. Radius Health has a 12-month low of $24.75 and a 12-month high of $77.10. The stock’s 50 day moving average is $54.72 and its 200-day moving average is $40.96. The firm’s market cap is $2.44 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/hc-wainwright-increases-radius-health-inc-rdus-price-target-to-71-00.html
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.06. During the same period last year, the business posted ($0.61) EPS. On average, analysts anticipate that Radius Health will post ($3.95) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RDUS. BlackRock Fund Advisors raised its position in Radius Health by 2.5% in the first quarter. BlackRock Fund Advisors now owns 1,367,137 shares of the biopharmaceutical company’s stock valued at $42,983,000 after buying an additional 33,421 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Radius Health by 0.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 807,600 shares of the biopharmaceutical company’s stock valued at $25,391,000 after buying an additional 3,792 shares during the last quarter. State Street Corp raised its position in Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock valued at $49,938,000 after buying an additional 453,302 shares during the last quarter. Bellevue Group AG purchased a new position in Radius Health during the first quarter valued at $1,258,000. Finally, JPMorgan Chase & Co. raised its position in Radius Health by 79.7% in the first quarter. JPMorgan Chase & Co. now owns 147,112 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 65,259 shares during the last quarter. 99.91% of the stock is currently owned by institutional investors and hedge funds.
About Radius Health
Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.